Why the study?
There is debate over which cardioplegic solution provides the highest degree of myocardial protection during minimally invasive valve surgery.
Does a specific cardioplegic solution improve myocardial protection in patients undergoing minimally invasive valve surgery?
Does a specific cardioplegic solution improve myocardial protection in patients undergoing minimally invasive valve surgery?
Current literature shows no superiority of any specific cardioplegic solution for myocardial protection during minimally invasive valve surgery.
No cardioplegic solution shows superiority for myocardial protection in minimally invasive valve surgery; leaves open optimal choice pending randomized trials.
Cardioplegic solutions are used in cardiac surgery to achieve controlled cardiac arrest during operations, making surgery safer. Cardioplegia can either be blood or crystalloid based, with perceived pros and cons of each type. Whilst it is known that cardioplegia causes cardiac arrest, there is debate over which cardioplegic solution provides the highest degree of myocardial protection during arrest. Myocardial damage is measured post-operatively by biomarkers such as serum TnT, TnI or CK-MB. It is known that the outcomes of minimally invasive valve surgery are comparable to full sternotomy valve operations. Despite there being a wide diversity in use of different cardioplegic solutions across the world, this comprehensive literature review found no superiority of one cardioplegic solution over the other for myocardial protection during minimally invasive valve procedures.
No takes yet. Share an insight, caveat, or question.
Russell et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: